Walleye Capital LLC Takes $309,000 Position in Inari Medical, Inc. (NASDAQ:NARI)

Walleye Capital LLC bought a new position in Inari Medical, Inc. (NASDAQ:NARI) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 6,058 shares of the company’s stock, valued at approximately $309,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of Inari Medical by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 5,628,875 shares of the company’s stock valued at $287,354,000 after purchasing an additional 30,702 shares during the period. Jennison Associates LLC lifted its stake in Inari Medical by 11.8% during the fourth quarter. Jennison Associates LLC now owns 1,763,258 shares of the company’s stock valued at $90,014,000 after buying an additional 186,617 shares in the last quarter. American Century Companies Inc. boosted its holdings in shares of Inari Medical by 9.1% in the fourth quarter. American Century Companies Inc. now owns 1,068,487 shares of the company’s stock worth $54,546,000 after buying an additional 89,108 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Inari Medical by 2.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 465,962 shares of the company’s stock worth $23,787,000 after acquiring an additional 11,990 shares in the last quarter. Finally, Principal Financial Group Inc. raised its holdings in shares of Inari Medical by 5.2% during the fourth quarter. Principal Financial Group Inc. now owns 308,903 shares of the company’s stock valued at $15,769,000 after acquiring an additional 15,368 shares during the period. 90.98% of the stock is owned by institutional investors and hedge funds.

Inari Medical Price Performance

Shares of NARI opened at $79.97 on Friday. Inari Medical, Inc. has a 12 month low of $37.23 and a 12 month high of $79.99. The company’s fifty day moving average is $79.97 and its 200-day moving average is $66.54. The firm has a market cap of $4.68 billion, a price-to-earnings ratio of -59.24 and a beta of 1.02.

Wall Street Analyst Weigh In

A number of research firms recently commented on NARI. Robert W. Baird reaffirmed a “neutral” rating and issued a $80.00 price objective (down previously from $81.00) on shares of Inari Medical in a research note on Tuesday, January 7th. Piper Sandler lifted their price target on Inari Medical from $52.00 to $80.00 and gave the company a “neutral” rating in a report on Tuesday, January 7th. Baird R W lowered Inari Medical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 7th. Canaccord Genuity Group restated a “hold” rating and set a $80.00 price objective (up from $74.00) on shares of Inari Medical in a research report on Tuesday, January 7th. Finally, BTIG Research reiterated a “neutral” rating on shares of Inari Medical in a report on Wednesday, January 8th. Twelve equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $68.00.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.